Human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, suppress proliferation and induce differentiation in HL-60 cells

Peptides

Volumn 30, Issue 8, 2009, Pages 1514-1522

  Zhao, You Li ^a   Tao, Yan ^a   Fu, Cai Yun ^c   Kong, Zi Qing ^a   Chen, Qiang ^a   Wang, Rui ^a,b  

^a North West Normal University   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Differentiation; h HK 1 and h HK 1(4 11); HL 60; Proliferation inhibition; SR140333 and SR48968

Indexed keywords

HEMOKININ 1; HEMOKININ 1[4-11]; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ A; NEUROKININ B; NITROBLUE TETRAZOLIUM; NOLPITANTIUM; SAREDUTANT; SUBSTANCE P; TACHYKININ; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; INHIBITION KINETICS; MAMMAL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION;

BENZAMIDES; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; HL-60 CELLS; HUMANS; NEUROTRANSMITTER AGENTS; PIPERIDINES; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; TACHYKININS;

MAMMALIA;

EID: 67650596616     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.04.024     Document Type: Article

References (45)

1. Anazetti M.C., Melo P.S., Duran N., and Haun M. Comparative cytotoxicity of dimethylamide-crotonin in the promyelocytic leukemia cell line (HL-60) and human peripheral blood mononuclear cells. Toxicology 188 (2003) 261-274
2. Baehner R.L., and Nathan D.G. Quantitative nitroblue tetrazolium test in chronic granulomatous disease. N Engl J Med 278 (1986) 971-976
3. Bellucci F., Carini F., Catalani C., Cucchi P., Lecci A., Meini S., et al. Pharmacological profile of the novel mammalian tachykinin, hemokinin 1. Br J Pharmacol 135 (2002) 266-274
4. Berger A., and Paige C.J. Hemokinin-1 has substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J Neuroimmunol 164 (2005) 48-56
5. Berger A., Tran A.H., and Paige C.J. Co-regulated decrease of Neurokinin-1 receptor and Hemokinin-1 gene expression in monocytes and macrophages after activation with pro inflammatory cytokines. J Neuroimmunol 187 (2007) 83-93
6. Camarda V., Rizzi A., Calo G., Guerrini R., Salvadori S., and Regoli D. Pharmacological profile of hemokinin 1: a novel member of the tachykinin family. Life Sci 71 (2002) 363-370
7. Campbell M.J., Reddy G.S., and Koeffler H.P. Vitamin D3 analogs and their 24-Oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66 (1997) 413-425
8. Devi L. In: Fricker L.D. (Ed). Peptide biosynthesis and processing (1991), CRC Press, Florida 175-198
9. Eugenia Riveiro M., Shayo C., Monczor F., Fernandez N., Baldi A., De Kimpe N., et al. Induction of cell differentiation in human leukemia U-937 cells by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon polystachyum. Cancer Lett 210 (2004) 179-188
10. Fan Y.Z., Chang H., Yu Y., Liu J., Zhao L., Yang D.J., et al. Thymopentin (TP5), an immunomodulatory peptide, suppresses proliferation and induces differentiation in HL-60 cells. BBA: Mol Cell Res 1763 (2006) 1059-1066
11. Fu C.Y., Zhao Y.L., Dong L., Chen Q., Ni J.M., and Wang R. In vivo characterization of the effects of human hemokinin-1 and human hemokinin-1(4-11), mammalian tachykinin peptides, on the modulation of pain in mice. Brain Behav Immun 22 (2008) 850-860
12. Jeurissen F., Kavelaars A., Korstjens M., Broeke D., Franklin R.A., Gelfand E.W., et al. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase. J Immunol 152 (1994) 2987-2994
13. Kavelaars A., Jeurissen F., Von Frijtag Drabble Kunzel J., Van Roijen J.H., Rijkers G.T., and Heijnen C.J. Substance P induces a rise in intracellular calcium concentration in human T lymphocytes in vitro: evidence of a receptor-independent mechanism. J Neuroimmunol 42 (1993) 61-70
14. Kong Z.Q., Fu C.Y., Chen Q., and Wang R. Cardiovascular responses to intravenous administration of human hemokinin-1 and its truncated form hemokinin-1(4-11) in anesthetized rats. Eur J Pharmacol 590 (2008) 310-316
15. Kurtz M.M., Wang R., Clements M.K., Cascieri M.A., Austin C.P., Cunningham B.R., et al. Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene 296 (2002) 205-212
16. Laurenzi M.A., Person M.A.A., Dalsgaard C.J., and Haegerstrand A. The neuropeptide substance P stimulates production of interleukin 1 in human blood monocytes: activated cells are preferentially influenced by the neuropeptide. Scand J lmmunol 31 (1990) 529-533
17. Liu L., Shack S., Stetler-Stevenson W.G., Hudgins W.R., and Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol 103 (1994) 335-340
18. Longmore J., Hill R.G., and Hargreaves R.J. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can J Physiol Pharm 75 (1997) 612-621
19. Lotz M., Vaughn J.H., and Carson D.A. Effects of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241 (1988) 1218-1221
20. Lucas D.L., Tanuma S., Davies P.J., Wright D.G., and Johnson G.S. Maturation of human promyelocytic leukemia cells induced by nicotinamide: evidence of a regulatory role for ADP-ribosylation of chromosomal proteins. J Cell Physiol 121 (1984) 334-340
21. Maggi C.A. The effects of tachykinins on inflammatory and immune cells. Regul Pept 70 (1997) 75-90
22. McGillis J., Mitsuhashi M., and Payan D. Immunologic properties of substance P. In: Ader R., Felten D.L., and Cohen N. (Eds). Psychoneuroimmunology. 2nd ed. (1991), Academic Press, San Diego, CA 209-223
23. Montenegro R.C., De Vasconcellos M.C., Bezerra F.S., Andrade-Neto M., Pessoa C., De Moraes M.O., et al. Pisosterol induces monocytic differentiation in HL-60 cells. Toxicol In Vitro 21 (2007) 795-800
24. Mosmann T. Rapid colorimetric assays for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 16 (1983) 55-63
25. Mousli M., Bronner C., Landry Y., Bockaert J., and Rouot B. Direct activation of GTP-binding regulatory proteins (G-proteins) by substance P and compound 48/80. FEBS Lett 259 (1990) 260-262
26. Mousli M., Bued J.L., Bronner C., Rouot B., and Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 11 (1990) 358-362
27. Nelson D.A., and Bost K.L. Non-neuronal mammalian tachykinin expression. Front Biosci 9 (2004) 2166-2176
28. Novichenko N., Konno S., Nakajima Y., Hsieh T.C., Xu W., Turo K., et al. Growth attenuation in a human prostate cell line mediated by a phorbol ester. Proc Soc Exp Biol Med 209 (1995) 152-156
29. Page N.M., Bell N.J., Gardiner S.M., Manyonda I.T., Brayley K.J., Strange P.G., et al. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proc Natl Acad Sci U S A 100 (2003) 6245-6250
30. Palma C., and Maggi C.A. The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 67 (2000) 985-1001
31. Patacchini R., and Maggi C.A. Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 429 (2001) 13-21
32. Patak E., Pennefather J.N., Candenas M.L., Kerr K., Exintaris B., Ziccone S., et al. Functional characterisation of hemokinin-1 in mouse uterus. Eur J Pharmacol 601 (2008) 148-153
33. Payan D.G. Neuropeptides and inflammation. Annu Rev Med 40 (1989) 341-352
34. Payan D.G., Levine J.D., and Goetzl E.J. Modulation of immunity and hypersensitivity by sensory neuropeptides. J Immunol 132 (1983) 1601-1604
35. Pennefather J.N., Patak E., Ziccone S., Lilley A., Pinto F.M., Page N.M., et al. Regulation of the stimulant actions of neurokinin A and human hemokinin-1 on the human uterus: a comparison with histamine. Biol Reprod 75 (2006) 334-341
36. Pernow B. Substance P. Pharmacol Rev 35 (1983) 85-141
37. Regoli D., Drapeau G., Dion S., and D'Orle′ans-Juste P. Pharmacological receptors for substance P and neurokinins. Life Sci 40 (1987) 109-117
38. Repke H., and Bienert M. Mast cell activation a receptor-independent mode of substance P action. FEBS Lett 221 (1987) 236-240
39. Ruff M.R., Wahl S.M., and Pert C.B. Substance P receptor mediated chemotaxis of human monocytes. Peptides 6 (1985) 107-111
40. Samid D., Shack S., and Myers C.E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91 (1993) 2288-2295
41. 2+ concentration and inositol phosphate formation. J Immunol 141 (1988) 2118-2124
42. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharmacol Rev 54 (2002) 285-322
43. Stanisz A.M., Befus D., and Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 136 (1986) 152-156
44. Zhang Y., Lu L., Furlonger C., Wu G.E., and Paige C.J. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 1 (2000) 392-397
45. Zuco V., Supino R., Righetti S.C., Cleris L., Marchesi E., Passerine Gambacorti C., et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175 (2002) 17-25